Autologous chimeric antigen receptor T cell therapy(Shanghai Keqi Pharmaceutical Technology)

N/A

Report date: 2024/08/29 14:50:15

Base Information

Drug NameAutologous chimeric antigen receptor T cell therapy(Shanghai Keqi Pharmaceutical Technology)

Drug Alias NameKQ-L6自体嵌合抗原受体T细胞Autologous CART-TM4SF1 cells(Shanghai Keqi Pharmaceutical Technology)Autologous PTA chimeric antigen receptor T cells(Shanghai Keqi Pharmaceutical Technology)KQ-L6

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionTransmembrane 4 L6 family member 1 inhibitors

TargetsTransmembrane 4 L6 family member 1

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Keqi Pharmaceutical Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A